Due to their ability to be a part of protein complexes, modern HAT inhibitors are unstable, have low activity, or lack of selectivity [74]; however, the development of more selective HAT inhibitors will undoubtedly be of interest for future cancer therapy [75], and possibly for stroke therapy. Here, TMPRSS11D is linked to Stroke.